Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 8Glioma 7Breast Neoplasms 7Neoplasms 6Glioblastoma 6Pancreatic Neoplasms 5Neoplasm Metastasis 5Recurrence 4Lymphoma, B-Cell 4Lymphoma 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Multiple Myeloma 3Melanoma 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Sarcoma 2Pancreatic Ductal Adenocarcinoma 2Myelodysplastic Syndromes 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoglobulin Light-chain Amyloidosis 2Carcinoma, Transitional Cell 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Burkitt Lymphoma 2Advanced Solid Tumors 2Uterine Cervical Neoplasms 1

Interventions

sacituzumab govitecan 1pembrolizumab 1erdafitinib 1enfortumab vedotin 1avelumab 1Vinblastine 1Paclitaxel 1Nivolumab 1Methotrexate 1Gemcitabine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Muscle Invasive Bladder Urothelial Carcinoma × 30 days × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡